Please assess the completion status of the following clinical trial:

Trial Title: Effects of Human Leptin Replacement

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Congenital leptin deficiency (these are only 3 adult individuals in the world that have been identified as leptin-naïve thus far).~Exclusion Criteria:~* Pregnant, trying to become pregnant, breast-feeding an infant or sexually active women, not using contraception.~* Subjects with hemoglobin levels below 12 g/dl.~* Subjects whose body contains a ferromagnetic implanted device that might produce a safety hazard during fMRI.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Recombinant methionyl human leptin (Type: EXPERIMENTAL): Participants with congenital leptin deficiency will receive the Recombinant methionyl human leptin intervention subcutaneously, once a day with a dose of 0.02 to 0.04 mg/kg (adjusted according to weight loss).

Based on this trial design, predict the completion outcome and termination type (if applicable).